GWM
VIR icon

Gilpin Wealth Management’s Vir Biotechnology VIR Stock Holding History

Gilpin Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174 Sell
17
-2
-11% -$19 ﹤0.01% 943
2026
Q1 		$171 Buy
19
+15
+375% +$120 ﹤0.01% 884
2025
Q4 		$25 Buy
+4
New +$24 ﹤0.01% 969

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Gilpin Wealth Management's VIR Position: Q2 2026 in Review

Gilpin Wealth Management reduced its Vir Biotechnology (VIR) stake by 11% in Q2 2026, selling an estimated $19 and leaving 17 shares worth $174. The position accounts for ﹤0.01% of the portfolio, ranked #943.

Gilpin Wealth Management first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Gilpin Wealth Management held 17 shares of Vir Biotechnology worth $174 as of Q2 2026.
  • Gilpin Wealth Management sold 2 Vir Biotechnology shares in Q2 2026, an estimated $19.
  • Vir Biotechnology made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q2 2026, its #943 holding.
  • Gilpin Wealth Management first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.